Patents by Inventor Lai-Ming Ching
Lai-Ming Ching has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11826316Abstract: Pharmaceutical compositions comprising 3-aminoisoxazolopyridine compounds of the Formula I having IDO1 and/or TDO inhibitory activity are described, where W is CR1, N or N-oxide; X is CR2, N or N-oxide; Y is CR3, N or N-oxide; Z is CR4, N or N-oxide; and at least one of W, X, Y, and Z is N or N-oxide; and R9 and R10 are as defined. Also described are methods of using such compounds in the treatment of various conditions, such as cancer.Type: GrantFiled: October 15, 2020Date of Patent: November 28, 2023Assignee: AUCKLAND UNISERVICES LIMITEDInventors: Brian Desmond Palmer, Lai Ming Ching, Swarnalatha Akuratiya Gamage
-
Publication number: 20220411438Abstract: Pharmaceutical compositions comprising 3-aminoisoxazolopyridine compounds of the Formula I having IDO1 and/or TDO inhibitory activity are described, where W is CR1, N or N-oxide; X is CR2, N or N-oxide; Y is CR3, N or N-oxide; Z is CR4, N or N-oxide; and at least one of W, X, Y, and Z is N or N-oxide; and R9 and R10 are as defined. Also described are methods of using such compounds in the treatment of various conditions, such as cancer.Type: ApplicationFiled: August 15, 2022Publication date: December 29, 2022Inventors: Brian Desmond Palmer, Lai-Ming Ching
-
Patent number: 11414428Abstract: Pharmaceutical compositions comprising 3-aminoisoxazolopyridine compounds of the Formula I having IDO1 and/or TDO inhibitory activity are described, where W is CR1, N or N-oxide; X is CR2, N or N-oxide; Y is CR3, N or N-oxide; Z is CR4, N or N-oxide; and at least one of W, X, Y, and Z is N or N-oxide; and R9 and R10 are as defined. Also described are methods of using such compounds in the treatment of various conditions, such as cancer.Type: GrantFiled: August 25, 2016Date of Patent: August 16, 2022Assignee: Auckland UniServices LimitedInventors: Brian Desmond Palmer, Lai-Ming Ching
-
Publication number: 20210145839Abstract: Pharmaceutical compositions comprising 3-aminoisoxazolopyridine compounds of the Formula I having IDO1 and/or TDO inhibitory activity are described, where W is CR1, N or N-oxide; X is CR2, N or N-oxide; Y is CR3, N or N-oxide; Z is CR4, N or N-oxide; and at least one of W, X, Y, and Z is N or N-oxide; and R9 and R10 are as defined. Also described are methods of using such compounds in the treatment of various conditions, such as cancer.Type: ApplicationFiled: October 15, 2020Publication date: May 20, 2021Inventors: Brian Desmond Palmer, Lai Ming Ching, Swarnalatha Akuratiya Gamage
-
Patent number: 10888567Abstract: Pharmaceutical compositions comprising 3-aminoisoxazolopyridine compounds of the Formula I having IDO1 and/or TDO inhibitory activity are described, where W is CR1, N or N-oxide; X is CR2, N or N-oxide; Y is CR3, N or N-oxide; Z is CR4, N or N-oxide; and at least one of W, X, Y, and Z is N or N-oxide; and R9 and R10 are as defined. Also described are methods of using such compounds in the treatment of various conditions, such as cancer.Type: GrantFiled: August 12, 2015Date of Patent: January 12, 2021Assignee: Auckland UniServices LimitedInventors: Brian Desmond Palmer, Lai Ming Ching, Swarnalatha Akuratiya Gamage
-
Publication number: 20180244692Abstract: Pharmaceutical compositions comprising 3-aminoisoxazolopyridine compounds of the Formula I having IDO1 and/or TDO inhibitory activity are described, where W is CR1, N or N-oxide; X is CR2, N or N-oxide; Y is CR3, N or N-oxide; Z is CR4, N or N-oxide; and at least one of W, X, Y, and Z is N or N-oxide; and R9 and R10 are as defined. Also described are methods of using such compounds in the treatment of various conditions, such as cancer.Type: ApplicationFiled: August 25, 2016Publication date: August 30, 2018Inventors: Brian Desmond Palmer, Lai-Ming Ching
-
Publication number: 20170224701Abstract: Pharmaceutical compositions comprising 3-aminoisoxazolopyridine compounds of the Formula I having IDO1 and/or TDO inhibitory activity are described, where W is CR1, N or N-oxide; X is CR2, N or N-oxide; Y is CR3, N or N-oxide; Z is CR4, N or N-oxide; and at least one of W, X, Y, and Z is N or N-oxide; and R9 and R10 are as defined. Also described are methods of using such compounds in the treatment of various conditions, such as cancer.Type: ApplicationFiled: August 12, 2015Publication date: August 10, 2017Inventors: Brian Desmond Palmer, Lai Ming Ching, Swarnalatha Akuratiya Gamage
-
Patent number: 7585893Abstract: The present invention relates to the use of compounds such as compounds of the xanthenone acetic acid class such as 5,6-dimethylxanthenone-4-acetic acid (DMXAA) for the treatment of cancer, wherein the compounds are administered gastrointestinally, preferably orally. More particularly, the invention is concerned with the use of such compounds, wherein the compound is delivered to the site of action in the patient to be treated in two or more doses.Type: GrantFiled: April 28, 2005Date of Patent: September 8, 2009Assignee: Cancer Research Technology LimitedInventors: Bruce Charles Baguley, Lai-Ming Ching, Philip Kestell, Liangli Zhao
-
Patent number: 7510830Abstract: Methods and compositions are provided for treating cancer, the methods including the step administering, either sequentially or simultaneously, (i) a compound of the xanthenone acetic acid group of compounds, and (ii) at least one compound selected from compounds which modulate TNF production and compounds which act on biochemical pathways leading to TNF synthesis. Compositions include a combination of (i) and (ii) above, together with acceptable pharmaceutical carriers and/or vehicles.Type: GrantFiled: January 14, 2003Date of Patent: March 31, 2009Assignee: Cancer Research Technology LimitedInventors: Bruce Charles Baguley, Lai-Ming Ching, Martin Philpott
-
Publication number: 20090062377Abstract: The present invention relates to synergistic combinations of the compounds of formula I such as compounds of the xanthenone acetic acid class such as 5,6-dimethylxanthenone-4-acetic acid (DMXAA) and NSAIDs, in particular diclofenac, which have anti-tumour activity. More particularly, the invention is concerned with the use of such combinations in the treatment of cancer and pharmaceutical compositions containing said combinations.Type: ApplicationFiled: November 3, 2008Publication date: March 5, 2009Inventors: Liang-Chuan Steve Wang, James William Paxton, Lai-Ming Ching, Bruce Charles Baguley, Philip Kestell
-
Patent number: 7462642Abstract: The present invention relates to synergistic combinations of the compounds of formula I such as compounds of the xanthenone acetic acid class such as 5,6-dimethylxanthenone-4-acetic acid (DMXAA) and NSAIDs, in particular diclofenac, which have anti-tumor activity. More particularly, the invention is concerned with the use of such combinations in the treatment of cancer and pharmaceutical compositions containing said combinations.Type: GrantFiled: September 22, 2004Date of Patent: December 9, 2008Assignee: Cancer Research Technology LimitedInventors: Liang-Chuan Steve Wang, James William Paxton, Lai-Ming Ching, Bruce Charles Baguley, Philip Kestell
-
Publication number: 20080167272Abstract: The present invention concerns certain hydrolytic thalidomide metabolites, combinations thereof with other anti-neoplastic compounds and their use in the treatment of solid tumours.Type: ApplicationFiled: June 16, 2006Publication date: July 10, 2008Applicant: Auckland Uniservices LimitedInventors: Lai-Ming Ching, Brian D. Palmer
-
Publication number: 20070082937Abstract: The present invention relates to synergistic combinations of the compounds of formula (I) such as compounds of the xanthenone acetic acid class such as 5,6dimethylxanthenone-4-acetic acid (DMXAA) and a selective COX-2 inhibitor, in particular rofecoxib, which have anti-tumour activity. More particularly, the invention is concerned with the use of such combinations in the treatment of cancer and pharmaceutical formulations containing said combinations.Type: ApplicationFiled: September 2, 2004Publication date: April 12, 2007Applicant: Cancer Research Technology LimitedInventors: Bruce Baguley, James Paxton, Liang-Chuan Wang, Philip Kestell, Lai-Ming Ching
-
Publication number: 20060009505Abstract: The present invention relates to the use of compounds such as compounds of the xanthenone acetic acid class such as 5,6-dimethylxanthenone-4-acetic acid (DMXAA) for the treatment of cancer, wherein the compounds are administered gastrointestinally, preferably orally. More particularly, the invention is concerned with the use of such compounds, wherein the compound is delivered to the site of action in the patient to be treated in two or more doses.Type: ApplicationFiled: April 28, 2005Publication date: January 12, 2006Inventors: Bruce Baguley, Lai-Ming Ching, Philip Kestell, Liangli Zhao
-
Publication number: 20050131059Abstract: The present invention relates to synergistic combinations of the compounds of formula I such as compounds of the xanthenone acetic acid class such as 5,6-dimethylxanthenone-4-acetic acid (DMXAA) and NSAIDs, in particular diclofenac, which have anti-tumour activity. More particularly, the invention is concerned with the use of such combinations in the treatment of cancer and pharmaceutical compositions containing said combinations.Type: ApplicationFiled: September 22, 2004Publication date: June 16, 2005Inventors: Liang-Chuan Wang, James Paxton, Lai-Ming Ching, Bruce Baguley, Philip Kestell
-
Publication number: 20040087611Abstract: Methods and composition are provided for treating cancer, the methods including the step a administering, either sequentially or simultaneously, (i) a compound of the xanthenone acetic acid group of compounds, and (ii) at least one compound selected from compounds which modulate TNF production and compounds which act on biochemical pathways leading to TNF synthesis. Compositions include a combination of (i) and (ii) above, together with acceptable pharmaceutical carriers and/or vehicles.Type: ApplicationFiled: January 14, 2003Publication date: May 6, 2004Inventors: Bruce Charles Baguley, Lai-Ming Ching, Martin Philpott
-
Publication number: 20040086498Abstract: A method is provided for treating mammals, including humans, with advanced or large-tumour burdens. The method involves administering an immunotherapeautic agent in conjunction with a tumour growth restricting agent, in amounts effective to eradicate any advanced or large tumours present. In preferred embodiments, the immunotherapeautic agent comprises a T-cell co-stimulatory cell adhesion molecule (CAM) or a mammalian expression vector containing DNA which encodes a T-cell co-stimulatory CAM, such as B7.1, and the tumour growth restricting agent is flavone acetic acid, 5,6-dimenthyl-xanthenone-4-acetic acid, or an agent which disrupts the expression or activity of hypoxia-inducible factor-1 (HIF-1).Type: ApplicationFiled: December 11, 2001Publication date: May 6, 2004Inventors: Geoffrey W. Krissansen, Jagat Rakesh Kanwar, Lai-Ming Ching
-
Publication number: 20030003092Abstract: A method is provided for treating mammals, including humans, with advanced or large-tumour burdens. The method involves administering an immunotherapeautic agent in conjunction with a tumour growth restricting agent, in amounts effective to eradicate any advanced or large tumours present. In preferred embodiments, the immunotherapeautic agent comprises a T-cell co-stimulatory cell adhesion molecule (CAM) or a mammalian expression vector containing DNA which encodes a T-cell co-stimulatory CAM, such as B7.1, and the tumour growth restricting agent is flavone acetic acid, 5,6-dimenthyl-xanthenone-4-acetic acid, or an agent which disrupts the expression or activity of hypoxia-inducible factor-1 (HIF-1).Type: ApplicationFiled: December 11, 2001Publication date: January 2, 2003Inventors: Geoffrey W. Krissansen, Jagat Rakesh Kanwar, Lai-Ming Ching